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ABSTRACT
Objective: The objective of the present study was to develop and validate a new stability-indicating method for the quantification of lenvatinib 
mesylate in bulk drug and pharmaceutical dosage form using ultra performance liquid chromatography (UPLC).
Methods: The optimized chromatographic conditions for elution of drug included UPLC HSS C18 (100 mm × 2.1 mm, 1.8 m) column, mixture of 
0.1% orthophosphoric acid and acetonitrile (50:50 v/v%) mobile phase run on an isocratic mode at a flow rate of 0.3 mL/min, 240 nm detection 
wavelength, and column oven temperature maintained at 30°C.
Results: The retention time for lenvatinib was found to be 1.24 min. The developed method was validated for various validation parameters in 
accordance with the International Conference on Harmonization guidelines. The method obeyed Beer’s law in the concentration range of 2.5–
15 µg/mL with a correlation coefficient of 0.9996. The percentage relative standard deviation and percentage recovery were determined to be 0.4 and 
99.66–100.30%, respectively. The developed method was found to be accurate, precise, specific, linear, rugged, and robust. Forced degradation studies 
were conducted by exposing the drug to diverse stress conditions such as acidic, basic, peroxide, neutral, photolytic, and thermal conditions. The net 
degradation was obtained within the limits.
Conclusion: The developed method for the estimation of lenvatinib can be employed to routine analysis of pharmaceutical dosage form.
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INTRODUCTION
Lenvatinib mesylate (Fig. 1) [1,2] chemically known as 4-[3-chloro-4-
(N’-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamide 
methanesulfonate. It is a white to pale reddish-yellow powder, slightly 
soluble in water and practically insoluble in ethanol. It is a pKa value of 
5.05. It belongs to anticancer category and utilized for the treatment of 
various kinds of thyroid cancer [3,4]. It acts as receptor tyrosine kinase 
inhibitor that inhibits the kinase activities of vascular endothelial 
growth factor receptors [5]. It also inhibits other RKTs that have been 
implicated in pathogenic angiogenesis, tumor growth, and cancer 
progression in addition to their normal cellular functions, including 
fibroblast growth factor receptors.
Ultra performance liquid chromatography (UPLC) [6-8] is a relatively 
new technique giving new possibilities in liquid chromatography, 
especially concerning the decrease of time and solvent consumption. 
UPLC chromatographic system is designed in a special way to withstand 
extreme system back pressures.
In accordance to literature review, it was known that there were 
only few methods such as reverse-phase high-performance liquid 
chromatography (RP-HPLC) [9-11], ultraviolet (UV) spectroscopy [11], 
and liquid chromatography coupled with tandem mass spectrometry 
method [12-14] developed for the estimation of lenvatinib.
As there was no UPLC method developed for the estimation of 
lenvatinib, the present study was intended to develop and validate a 
stability-indicating UPLC method for the quantitative determination of 
lenvatinib in bulk drug and pharmaceutical dosage form.
METHODS
Chemicals and reagents
Lenvatinib mesylate working standard was supplied as a gift sample 
from Spectrum Labs, Hyderabad. Lenvima capsules were purchased 
from a local pharmacy. All the chemicals used for the development 
of the method were of AR grade purchased from Merck, Mumbai. All 
the solvents used were of HPLC grade purchased from Sigma-Aldrich, 
Mumbai.
Analytical conditions and instruments
The ACQUITY UPLC system equipped with binary solvent manager, 
sample manager, UV detector, and UPLC HSS C18 (100 mm × 2.1 mm, 
1.8 µ) column was used for the determination of lenvatinib. The 
analytical conditions included 0.1% orthophosphoric acid and 
acetonitrile (50:50 v/v%) as mobile phase run on an isocratic mode at 
a flow rate of 0.3 mL/min. The column was kept at 30°C and detection 
was done at 240 nm wavelength. Additional equipment included pH 
meter, ultrasonic bath sonicator, and weighing balance.
Preparation of mobile phase
Mixture of 0.1% aqueous orthophosphoric acid buffer and acetonitrile 
in the ratio of 50:50 v/v% was used as mobile phase.
Preparation of standard and sample solution
10 mg of lenvatinib working standard was dissolved in 100 ml of diluent. 
1 mL of the above standard stock solution was diluted to 10 mL diluent.
Average weight of 20 lenvima capsules was calculated and an amount 
equivalent to 10 mg of lenvatinib was dissolved in 100 mL of diluent. 
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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The above sample stock solution was filtered and diluted 1–10 mL with 
diluent.
Method validation
The developed method was validated in compliance with the 
International Conference on Harmonization (ICH) guidelines [15] the 
following parameters are as follows:
Accuracy
Accuracy of the method was established by preparing three 
concentration levels of 50%, 100%, and 150%. Then, percentage 
recovery was calculated.
Precision
Precision of the method was determined by injecting six solutions of 
sample and then percentage relative standard deviation (RSD) was 
calculated.
Specificity
For the determination of specificity of the method, a placebo solution 
was prepared and compared with the drug solution for any interference 
of placebo peak with the drug peak.
Linearity
For the linearity study, serial dilutions of the drug solution were 
prepared in the concentration range of 2.50–15 µg/mL. A graph 
was plotted by taking concentration on the x-axis and peak area on 
y-axis.
Limit of detection (LOD) and limit of quantitation (LOQ)
LOD and LOQ are calculated using standard deviation and slope of 
the calibration curve by placing in the formula mentioned in the ICH 
guidelines.
Ruggedness
Ruggedness was evaluated by performing precision on different days 
and the percentage RSD was calculated.
Robustness
Robustness was determined by varying the optimized conditions 
such as variation of the organic phase in the mobile phase by ± 10%, 
variation of flow rate by ±0.1 mL/min, and variation of column oven 
temperature by ±5°C.
Solution stability
Solution stability was assessed by performing the assay of drug 
solutions after storing for 24 h.
Forced degradation studies
Forced degradation studies [16] were conducted by exposing the 
drug solution to various degradation conditions such as acidic (2 N 
hydrochloric acid, 60°C for 30 min), basic (2 N sodium hydroxide 
[NaOH], 60°C for 30 min), oxidative (20% hydrogen peroxide [H2O2], 
60°C for 30 min), neutral (refluxing the drug in water for 6 h, 60°C), 
thermal (105°C for 6 h), and photolytic (UV chamber for 7 d) conditions. 
The net degradation for unusual conditions was noted.
RESULTS
DISCUSSION
For the development of a method for the estimation of lenvatinib, 
various mobile phases and stationary phases were tried to elute the 
drug with good peak parameters. The optimized conditions used 
were mobile phase consisting of composition 0.1% o-phosphoric 
acid and acetonitrile (50:50 v/v%) run on an isocratic mode with 
flow rate of 0.3 mL/min, UPLC HSS C18 (100 mm × 2.1 mm, 1.8 m) 
column maintained at 30°C temperature. Lenvatinib was detected at a 
wavelength of 240 nm as the drug shows maximum absorbance at that 
wavelength as shown in Fig. 2.
The standard solution, sample solution, and the blank solution were 
prepared as per the procedure mentioned above. The standard solution 
was injected into the UPLC system for evaluating the system suitability 
parameters. The results were presented in Table 1 and chromatograms 
were shown in Fig. 3.
The method was considered to be accurate as the percentage recovery 
for lenvatinib was found to be 99.66–100.30%. The percentage RSD for 
lenvatinib was determined to be 0.4, indicating that the method was 
precise. The developed method was found to be specific to the drug 
when compared with a placebo solution, as there was no interference 
Fig. 1: Chemical structure of lenvatinib mesylate
Fig. 2: Ultraviolet spectrum of lenvatinib
Table 1: Results of system suitability and validation parameters
Parameter Result
Precision (%RSD, n) 0.4
Accuracy (% Recovery, n) 99.66% - 100.30%
Specificity Specific, No 
interference
Linearity range (µg/ml) 2.5 – 15








Ruggedness (%RSD, n) Day 1 Day 2
0.5 0.4














Day 1 (0 h) Day 2 
 (After 24 h)
0.5 0.4
USP plate count 2422
USP tailing factor 1.16
n: Number of samples, i.e., 6 samples, %RSD: % Relative standard deviation
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The method was found to perform Beer’s law in the concentration range 
of 2.5–15 µg/mL with a correlation coefficient of 0.9996. The linearity 
plot was presented in Fig. 5.
The LOD and LOQ for lenvatinib were found to be 0.16 µg/mL and 
0.50 µg/mL, respectively. The method was found to be rugged as the 
percentage RSD when compared with day difference was found to be 
within the limits, robust when did by varying the optimized conditions 
and stable in solution form also after storing for 24 h.
Forced degradation studies indicated that the samples remained 
stable under different stress conditions such as acidic, basic, oxidative, 
photolytic, and thermal conditions. The net degradation was considered 
to be within the limits. The results were outlined in Table 2 and 
chromatograms were shown in Fig. 6.
CONCLUSION
The new stability-indicating method was established for quantitative 
determination of lenvatinib in pharmaceutical dosage and bulk drug 
using UPLC. The developed method was validated in accordance with the 
ICH guidelines. The method was found to be accurate, precise, specific, 
linear, rugged, robust, and stable in solution. Forced degradation 
studies concluded that the drug was stable in various stress conditions.
This method can be applied to the routine analysis of lenvatinib in 
pharmaceutical dosage form.
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Fig. 3: (a) Ultra performance liquid chromatography (UPLC) chromatogram of lenvatinib standard solution, (b) UPLC chromatogram of 
lenvatinib sample solution, (c) UPLC chromatogram of blank solution
Fig. 4: Ultra performance liquid chromatography chromatogram 
of placebo solution
Fig. 5: Linearity plot of lenvatinib
Table 2: Results of forced degradation studies
Stress condition % Assay % Area of degradation peak % Degradation
2 N HCl for 30 min at 60°C 95.75 - 4.25
2 N NaOH for 30 min at 60°C 95.71 - 4.29
20% H2O2 for 30 min at 60°C 96.61 - 3.39
Water for 6 h at 60°C 99.04 - 0.96
UV light 200 wts/h or 7 d 97.27 - 2.73
105°C for 6 h 97.13 - 2.87
of placebo peak with the drug peak. The placebo chromatogram was 
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